Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

alpha 2u-globulin nephropathy and renal tumors in national toxicology program studies.

Doi AM, Hill G, Seely J, Hailey JR, Kissling G, Bucher JR.

Toxicol Pathol. 2007 Jun;35(4):533-40.

2.
3.
5.

Inhalation two-generation reproductive toxicity study of methyl isobutyl ketone in rats.

Nemec MD, Pitt JA, Topping DC, Gingell R, Pavkov KL, Rauckman EJ, Harris SB.

Int J Toxicol. 2004 Mar-Apr;23(2):127-43.

PMID:
15204733
6.
7.
8.

The effect of chronic progressive nephropathy on the incidence of renal tubule cell neoplasms in control male F344 rats.

Seely JC, Haseman JK, Nyska A, Wolf DC, Everitt JI, Hailey JR.

Toxicol Pathol. 2002 Nov-Dec;30(6):681-6.

10.

Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies).

National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services.

Natl Toxicol Program Tech Rep Ser. 2002 May;(504):1-357.

11.

Mechanisms of chemically induced renal carcinogenesis in the laboratory rodent.

Hard GC.

Toxicol Pathol. 1998 Jan-Feb;26(1):104-12. Review.

12.

Relationship of hydroquinone-associated rat renal tumors with spontaneous chronic progressive nephropathy.

Hard GC, Whysner J, English JC, Zang E, Williams GM.

Toxicol Pathol. 1997 Mar-Apr;25(2):132-43.

13.

Metabolic fate of methyl n-butyl ketone, methyl isobutyl ketone and their metabolites in mice.

Granvil CP, Sharkawi M, Plaa GL.

Toxicol Lett. 1994 Feb 15;70(3):263-7.

PMID:
8284793
15.

Ketone potentiation of haloalkane-induced hepato- and nephrotoxicity. I. Dose-response relationships.

Raymond P, Plaa GL.

J Toxicol Environ Health. 1995 Aug;45(4):465-80.

PMID:
7643433
16.

Ketone potentiation of haloalkane-induced hepato- and nephrotoxicity. II. Implication of monooxygenases.

Raymond P, Plaa GL.

J Toxicol Environ Health. 1995 Nov;46(3):317-28.

PMID:
7473860
17.

A test for differences between treatment means when several dose levels are compared with a zero dose control.

Williams DA.

Biometrics. 1971 Mar;27(1):103-17. No abstract available.

PMID:
5547548
18.

The comparison of several dose levels with a zero dose control.

Williams DA.

Biometrics. 1972 Jun;28(2):519-31. No abstract available.

PMID:
5037867
19.

Induction of liver growth by xenobiotic compounds and other stimuli.

Schulte-Hermann R.

CRC Crit Rev Toxicol. 1974 Sep;3(1):97-158. No abstract available.

PMID:
4373214
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk